Author:
Brola Waldemar, ,Kosno Krystian,Mitrosz Agnieszka, , ,
Abstract
Multiple sclerosis patients are by definition more susceptible to infections,
which dependents on the use of disease-modifying treatments. Depending on the mechanism
of action, individual disease-modifying treatments carry different risks. As a result,
patients require an individualised approach to initiating and continuing new treatments.
This problem became very important during the COVID-19 pandemic. In the case of drugs
with different mechanisms of action on the immune system, the impact of therapy on
susceptibility to SARS-CoV-2 infections and the course of COVID-19 should be considered.
Based on the risk/ benefit analysis for the patient, individual therapies have been
assigned recommendations: 1) low-risk therapies (glatiramer acetate, interferons,
dimethyl fumarate, teriflunomide) – discontinuation of therapy and delay of treatment
initiation is not recommended; 2) moderate-risk therapies (fingolimod, natalizumab,
ocrelizumab, cladribine) – require caution, individual risk/benefit assessment, risk
analysis of multiple sclerosis symptom exacerbation after drug discontinuation; 3)
high-risk therapies (alemtuzumab, mitoxantrone, haematopoietic stem cells
transplantation) – treatment initiation is not recommended, administration of subsequent
doses requires extreme caution. The article reviews the recommendations and publications
from the last 2 years, taking into account the changing views on the treatment of
multiple sclerosis in the time of COVID-19 pandemic.
Publisher
Medical Communications Sp. z.o.o.